Volker Teichgräber

7PUBLICATIONS
97CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Nov 18, 2025
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors.

Ignacio Melero, Josep Tabernero, Neeltje Steeghs

|Feb 03, 2025
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.

Eva Munoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu

|Oct 18, 2024
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma.

Aaron R Hansen, Carlos A Gomez-Roca, Debbie G J Robbrecht

|May 06, 2024
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer.

Hans Prenen, Sanjeev Deva, Bhumsuk Keam

|Apr 17, 2024
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors.

Neeltje Steeghs, Carlos Gomez-Roca, Kristoffer S Rohrberg

|Feb 06, 2024
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.

Solange Peters, Eric Angevin, Teresa Alonso-Gordoa

Pageof 2

Frequent Collaborators

7 joint publications

David Dejardin

7 joint publications

Jehad Charo

6 joint publications

Christophe Boetsch

6 joint publications

Stefan Evers